Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9CLV
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,535
Award facts
- Contract value 100% obligated
- $11,535.27 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $11,535.27 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on January 2, 2026, with an ultimate completion date of January 5, 2026. This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle valued through December 2026. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania.
This delivery order supports the Defense Health Agency's pharmaceutical supply chain for military healthcare operations. Dupixent (dupilumab) is a prescription biologic medication indicated for eczema, asthma, and chronic rhinosinusitis treatment. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The company's DLA contract vehicle enables flexible fulfillment of pharmaceutical needs for military healthcare systems and other federal agencies worldwide, with potential future realignment under the planned Pharmaceutical Prime Vendor Global Program Generation V contracts.
Quick answers
Who was awarded contract SPE2DR26F9CLV?
SPE2DR26F9CLV was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 2, 2026.
How much is contract SPE2DR26F9CLV worth?
The government has obligated $11,535 on SPE2DR26F9CLV.
Is contract SPE2DR26F9CLV an order under another contract?
Yes. SPE2DR26F9CLV is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F9CLV competed?
The extent of competition for SPE2DR26F9CLV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award